| Ytd | -2.73% | |
| 1y | 80.71% |
| Open | 3.55 | Prev Close | 3.53 | Low | 3.49 | High | 3.65 | Mkt Cap | 117.26M |
| Vol | 477.18K | Avg Vol | 475.29K | EPS | 2.26 | P/E | 1.56 | Forward P/E | -0.99 |
| Beta | 1.21 | Short Ratio | 4.57 | Inst. Own | 15.78% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.89 | 200-d Avg | 2.97 | 1yr Est | 14.33 |
FBIO News
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortres
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Jou
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 mill
Company to host conference call to discuss financial results and provide a corporate update on May 1
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 millio
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th
Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated
Company to host conference call to discuss financial results and provide a corporate update on March
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report)'s share price crossed above its 200-day movi
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved
Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey M
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its two hundred day mov
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its 200-day moving aver
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred fr
Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earn
On Friday morning, 446 companies hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
During Monday's morning session, 212 companies made new 52-week highs.
During the morning session on Friday, 178 stocks hit new 52-week highs.
Stocks That Hit 52-Week Lows On Monday
Stocks Which Set New 52-Week Low Yesterday, October 31st
Stocks Which Set New 52-Week Low Yesterday, October 11th
Stocks Which Set New 52-Week Low Yesterday, October 10th
Stocks Which Set New 52-Week Low Friday, October 5th